I hope Czechoslovakia sues Corrupticut and Yale. UCONN/Yale/SmithKline
experimented on children with a vaccine that would do no good in Europe just to
see how much damage the vaccine would do. They also knew LYMErix did not
prevent Lyme in the US.
Division of Rheumatology/Immunology, New England Medical
Center, Tufts University School of Medicine, Boston, Massachusetts 02111.
The antibody responses to the three genomic groups of
Borrelia burgdorferi (B. burgdorferi sensu stricto, Borrelia garinii, and
Borrelia afzelii) were determined in 97 German patients with various
manifestations of Lyme borreliosis. The geometric mean antibody titers in each
patient group, determined by ELISA, were similar with each antigen preparation.
By Western blotting, however, patients with meningopolyneuritis tended to
respond to more spirochetal polypeptides of B. garinii, the group 2 strain,
whereas those with arthritis recognized more antigens of B. afzelii, the group 3
strain (P < .03), as did those with acrodermatitis. Only 1 patient each with
erythema migrans, arthritis, or acrodermatitis had weak reactivity with outer
surface protein A (OspA), and none responded to OspB. It is concluded that
differences among the three groups of B. burgdorferi may result in variations in
the antibody response in European Lyme borreliosis. PMID: 8106763 [PubMed -
indexed for MEDLINE]
Department of Family Medicine, University of Connecticut
Health Center, Farmington, Connecticut 06030-1406, USA.
BACKGROUND AND OBJECTIVE: A recombinant lipoprotein vaccine
against Lyme disease, containing 30 microg of Borrelia burgdorferi outer surface
protein A (OspA) with aluminum adjuvant, has been shown in a large US field
trial of subjects >/=15 years of age to offer 76% efficacy against clinical Lyme
disease after 3 injections given at 0, 1, and 12 months. Lyme disease is also an
important problem in children; thus, OspA vaccine trials in children are needed.
The purpose of this study was to investigate the safety and immunogenicity of 2
different doses of lipoprotein OspA with aluminum adjuvant vaccine in healthy
children 5 to 15 years of age in a double-blind, randomized study. STUDY DESIGN:
In a double-blind study, 250 children from the Czech Republic were randomly
assigned to receive 15 microg or 30 microg of OspA vaccine at 0, 1, and 2
months. Serum samples, obtained before vaccination and 1 month after the second
and third doses, were analyzed for antiOspA antibody. Solicited and unsolicited
symptoms were collected from diary cards. RESULTS: Local pain at the injection
site was reported by approximately 76% of the 250 children. Headaches (after 5%
to 18% of the injections) and malaise (after 2% to 16% of the injections) were
the most frequently reported general symptoms. Local and generalized symptoms
were not different between the 15 microg and 30 microg groups, and all symptoms
resolved within 4 days. Both doses were highly immunogenic, with the 30 microg
dose eliciting higher antibody levels. Seroconversion occurred in 99% of the 250
children. CONCLUSIONS: The OspA vaccine against Lyme disease was well tolerated
and highly immunogenic in children. PMID: 10547245 [PubMed - indexed for MEDLINE]
Saint Michael the Archangel, defend us in battle. Be our protection against the wickedness and snares of the
May God rebuke him, we humbly pray;
and do Thou, O Prince of the Heavenly Host -
by the Divine Power of God - cast into hell, satan and all the evil spirits, who roam throughout the world seeking the ruin of souls.